Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Gel Approved for Clinical Study in Mild-to-Moderate Atopic Dermatitis
Published Time:
2023-03-21 17:39
Source:
Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.
This approval of the topical formulation VC005 marks another significant milestone in the development of VC005, following the approval of the oral tablet formulation for indications including inflammatory bowel disease (IBD), moderate-to-severe atopic dermatitis, ankylosing spondylitis (AS), and rheumatoid arthritis (RA). Currently, multiple Phase II clinical studies for the VC005 tablet have already been initiated.
About VC005
VC005 is a novel, highly potent, and selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces inflammatory responses and immune cell activation, thereby achieving therapeutic effects in inflammatory and autoimmune diseases. Compared to Upadacitinib(a currently marketed JAK inhibitor), VC005 exhibits lower JAK2 inhibitory activity(based on in vitro kinase assays), which may mitigate safety concerns associated with excessive JAK2 inhibition. The drug is currently being developed in two formulations: oral tablets and topical gel.
About JAK1
The JAK/STAT signaling pathway, mediated by JAK family kinases and downstream STAT transcription factors, plays a critical regulatory role in inflammatory and autoimmune diseases such as AS and AD. Current first-generation pan-JAK inhibitors non-selectively inhibit multiple JAK subtypes (e.g., JAK1, JAK2, TYK2) at similar potency levels. Excessive JAK2 inhibition is associated with severe adverse events, prompting the U.S. FDA to issue black box warnings for these agents. Consequently, second-generation selective JAK1 inhibitors like VC005, designed for enhanced safety and efficacy, represent a necessary evolution in therapy.
About AD
AD is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense pruritus, and eczematous lesions, significantly impairing patients’ quality of life. Epidemiological data indicate that AD affects up to 230 million individuals globally, including 70 million in China, with two-thirds classified as mild and one-third as moderate-to-severe. Prevalence continues to rise globally.
Traditional therapies such as glucocorticoids are limited by adverse effects and poor long-term outcomes, while treatment options for moderate-to-severe patients remain insufficient, leaving many without stable disease control. VC005’s development holds promise for bridging this gap.
Next Page
Related News
23
2017
/
08
Jiangsu Vcare Was Honored as Jiangbei New Area Lingque Enterprise
In 2017, the list of “Lingque” enterprises in Jiangbei New District of Nanjing was announced and Jiangsu Vcare Pharmaceutical Technology Co., Ltd. was successfully selected into the list. “Lingque” enterprises project aim to select a group of innovative SMEs with high growth in Jiangbei district and provide the selected enterprises with one-stop support such as equity investment, emergency turnover, loan interest subsidy, R&D subsidies, and etc.. To be successfully selected into the “Lingque” enterprises program is an inspiration to the company. Vcare keep integrating various resources to quickly become bigger and stronger to contribute to the development of Jiangbei New Area.
View Details
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
View Details
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.
View Details
15
2017
/
05
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare on May 12, 2017. The general manager Yongqiang Liu received the delegation.
View Details
24
2017
/
04
Jiangsu Vcare Held Mountain Climbing and Tug-of-war Competitions
Jiangsu Vcare organized mountain climbing and tug-of-war activities recently. The mountain climbing competition was divided into men's and women's groups, and each group competed for top three. The venue was located in Laoshan National Forest Park. Everyone climbed the top after efforts. Four teams consisting of Vcare’s two R&D center members conducted a tug-of-war competition after going down the mountain and finally "Lingya team" won the top spot. Everyone had fun.
View Details
30
2017
/
03
Jiangsu Vcare Held the First Quarter Fire Drill
In order to further improve the safety awareness of new employees, Jiangsu Vcare held a fire-fighting exercise on March 30, 2017. New employees had a deeper understanding of fire extinguishers through on-site explanation of the types, inspection methods and instructions of fire extinguishers. Everyone learned about fire-fighting procedures and the use of appliances. The exercise provided a safety guarantee for everyone’s life and work.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn